Total Payments
$38,019
2024 Payments
$2,329
Companies
44
Transactions
731
Medicare Patients
15,554
Medicare Billing
$2.9M
Payment Breakdown by Category
Food & Beverage$17,568 (46.2%)
Other$14,550 (38.3%)
Travel$5,137 (13.5%)
Consulting$500.00 (1.3%)
Education$263.48 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $17,568 | 690 | 46.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,550 | 12 | 38.3% |
| Travel and Lodging | $5,137 | 22 | 13.5% |
| Consulting Fee | $500.00 | 1 | 1.3% |
| Education | $263.48 | 6 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,928 | 49 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,872 | 169 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,665 | 32 | $0 (2024) |
| Abbott Laboratories | $3,830 | 51 | $0 (2024) |
| BIOTRONIK INC. | $2,184 | 15 | $0 (2018) |
| Medtronic, Inc. | $1,588 | 26 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,183 | 55 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,046 | 19 | $0 (2024) |
| Amgen Inc. | $1,010 | 55 | $0 (2024) |
| Boston Scientific Corporation | $945.11 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,329 | 98 | Novartis Pharmaceuticals Corporation ($549.43) |
| 2023 | $3,508 | 126 | Medtronic, Inc. ($1,229) |
| 2022 | $2,792 | 115 | Novartis Pharmaceuticals Corporation ($486.64) |
| 2021 | $4,161 | 101 | AstraZeneca Pharmaceuticals LP ($2,226) |
| 2020 | $4,489 | 70 | AstraZeneca Pharmaceuticals LP ($2,913) |
| 2019 | $4,803 | 112 | Abbott Laboratories ($2,276) |
| 2018 | $6,135 | 63 | Novartis Pharmaceuticals Corporation ($3,581) |
| 2017 | $9,802 | 46 | E.R. Squibb & Sons, L.L.C. ($5,980) |
All Payment Transactions
731 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.96 | General |
| Category: Cardiovascular | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $31.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/03/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $8.41 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: Cardiology | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.48 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $9.88 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $23.85 | General |
| 11/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.34 | General |
| Category: Cardiovascular | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: DIABETES | ||||||
| 11/01/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $17.57 | General |
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $10.55 | General |
| Category: Cardiovascular | ||||||
| 10/15/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: Cardiac Rhythm Management | ||||||
| 10/11/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Obesity | ||||||
| 10/10/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Not Applicable | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $121.36 | General |
| Category: Cardiovascular | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $121.36 | General |
| Category: Cardiovascular | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 4,065 | 8,191 | $2.6M | $789,384 |
| 2022 | 36 | 4,267 | 8,227 | $2.7M | $844,074 |
| 2021 | 36 | 3,905 | 6,818 | $2.4M | $756,959 |
| 2020 | 33 | 3,317 | 5,975 | $1.8M | $545,823 |
Total Patients
15,554
Total Services
29,211
Medicare Billing
$2.9M
Procedure Codes
141
All Medicare Procedures & Services
141 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 577 | 1,836 | $516,102 | $177,443 | 34.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 294 | 734 | $275,412 | $104,542 | 38.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 540 | 619 | $378,828 | $91,971 | 24.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 241 | 246 | $323,490 | $90,173 | 27.9% |
| 33285 | Insertion of heart rhythm monitor under skin | Office | 2023 | 16 | 16 | $207,051 | $56,217 | 27.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 327 | 342 | $176,130 | $51,507 | 29.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 231 | 944 | $125,552 | $41,492 | 33.0% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 239 | 439 | $184,380 | $30,803 | 16.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 59 | 419 | $28,911 | $19,975 | 69.1% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 80 | 283 | $43,582 | $18,382 | 42.2% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 23 | 23 | $41,699 | $16,448 | 39.4% |
| 93460 | Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 61 | 65 | $65,195 | $15,634 | 24.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 240 | 247 | $51,968 | $12,692 | 24.4% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 59 | 421 | $29,049 | $8,829 | 30.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 86 | $23,418 | $8,296 | 35.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 45 | 45 | $24,165 | $6,636 | 27.5% |
| 93285 | Programming of cardiac rhythm monitor system | Office | 2023 | 53 | 113 | $12,656 | $5,689 | 44.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 37 | $19,277 | $5,119 | 26.6% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 47 | 49 | $16,452 | $4,192 | 25.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 285 | 337 | $15,165 | $3,888 | 25.6% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 21 | 22 | $11,110 | $3,340 | 30.1% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 39 | 40 | $18,360 | $3,074 | 16.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 27 | $3,780 | $2,694 | 71.3% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 13 | 14 | $11,186 | $2,090 | 18.7% |
| 93226 | Electrocardiogram (ecg) 2-day continuous with report | Office | 2023 | 42 | 44 | $4,532 | $1,346 | 29.7% |
About Dr. Herman Lu, MD
Dr. Herman Lu, MD is a Cardiovascular Disease healthcare provider based in Murrieta, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073596912.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Herman Lu, MD has received a total of $38,019 in payments from pharmaceutical and medical device companies, with $2,329 received in 2024. These payments were reported across 731 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($17,568).
As a Medicare-enrolled provider, Lu has provided services to 15,554 Medicare beneficiaries, totaling 29,211 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 141 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Murrieta, CA
- Active Since 11/23/2005
- Last Updated 02/24/2015
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1073596912
Products in Payments
- ELIQUIS (Drug) $6,729
- FARXIGA (Drug) $5,446
- ENTRESTO (Drug) $4,874
- Mitra Clip system (Device) $1,997
- CardioMEMS HF System (Device) $1,452
- XARELTO (Drug) $1,333
- LifeVest (Device) $1,046
- LEQVIO (Drug) $980.32
- Repatha (Biological) $922.25
- LINQ II (Device) $891.98
- GENERAL - THERAPIES (Device) $801.21
- NEXLETOL (Drug) $681.41
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $634.14
- JARDIANCE (Drug) $452.88
- Artis icono floor (Device) $415.99
- Vascepa (Drug) $341.80
- Arcalyst (Drug) $334.16
- CAMZYOS (Drug) $331.34
- Ozempic (Drug) $292.17
- Reveal LINQ (Device) $281.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Murrieta
Frederick Wood, Md, MD
Cardiovascular Disease — Payments: $19,657
Cardiovascular Disease $19,657
Dr. Steve Jin, M.d, M.D
Cardiovascular Disease — Payments: $9,672
Cardiovascular Disease $9,672
Jeffrey Chung, Md, MD
Cardiovascular Disease — Payments: $6,343
Cardiovascular Disease $6,343
Ransi Somaratne, M.d, M.D
Cardiovascular Disease — Payments: $6,165
Cardiovascular Disease $6,165
Lance Reinherz, Md, MD
Cardiovascular Disease — Payments: $3,854
Cardiovascular Disease $3,854
Manila Zaman, M.d, M.D
Cardiovascular Disease — Payments: $2,905
Cardiovascular Disease $2,905